Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib + Fruquintinib in MET-amplified mCRC
NCT06980532Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glumetinib in metastatic colorectal cancer (mCRC). Primary endpoints: Recommended Phase II Dose at 18 weeks and Objective Response Rate at 18 weeks. Started Apr 2025; status: recruiting.
02
Drugs
glumetinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06980532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980532.